With respect to assay development, quality assurance and, ultimately, clinical adoption, the primary subject of this review, these advantages are critical. Implicit with these advantages, TMAs enable ...
In 1997, Juha Kononen, a postdoctoral fellow at the National Human Genome Research Institute, was pondering the significance of the recently developed DNA microarray. He was studying genetically ...
Barely five years ago, Juha Kononen, then at the National Cancer Institute, presented a straightforward way of constructing tissue microarrays (TMAs): a glass slide covered with as many as 1,000 cores ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback